Nilotinib

證據等級: L5

預測適應症: 1 個

Nilotinib: From Original Indication (Not Specified in Evidence Pack) to Dermatofibrosarcoma Protuberans

One-Sentence Summary

Nilotinib is a tyrosine kinase inhibitor (DrugBank DB04868); its original approved indication is not documented in this evidence pack (flagged as a data gap). The TxGNN model predicts it may be effective for Dermatofibrosarcoma Protuberans (DFSP), with 0 clinical trials and 1 publication currently supporting this direction, placing the candidate at an early, mechanism-driven research stage.

Quick Overview

Item	Content
Original Indication	Not documented in evidence pack (data gap)
Predicted New Indication	Dermatofibrosarcoma Protuberans
TxGNN Prediction Score	99.31%
Evidence Level	L4
US Market Status	Not Marketed
Number of NDAs	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data for nilotinib is not available in this evidence pack (flagged as a High-severity data gap). Based on the repurposing rationale provided, nilotinib is a second-generation tyrosine kinase inhibitor with inhibitory activity against BCR-ABL, KIT, and PDGFR.

DFSP’s characteristic molecular event is the COL1A1-PDGFB fusion gene, which drives constitutive activation of PDGFR-β and tumour proliferation. Because nilotinib directly inhibits PDGFR, it is mechanistically linked to the disease driver of DFSP.

Imatinib, a first-generation TKI with an overlapping target profile (including PDGFR), is already an approved/standard treatment for DFSP — this establishes a class-effect precedent supporting the plausibility of nilotinib’s activity. However, direct clinical data for nilotinib specifically in DFSP remain very limited, largely confined to case-level reports in patients who failed or were intolerant to imatinib.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
29408302	2018	Review	Pharmacological Research	Reviews the role of small-molecule PDGFR inhibitors (including nilotinib) in treating neoplastic disorders driven by PDGF/PDGFR signaling, supporting the mechanistic basis for PDGFR-driven tumours such as DFSP.

Cytotoxicity

Item	Content
Cytotoxicity Classification	Targeted therapy (BCR-ABL / PDGFR / KIT tyrosine kinase inhibitor)
Myelosuppression Risk	Please refer to the package insert warnings and precautions
Emetogenicity Classification	Please refer to the package insert warnings and precautions
Monitoring Items	Please refer to the package insert warnings and precautions
Handling Protection	Please refer to the package insert warnings and precautions

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: Evidence is currently limited to a mechanistic rationale and a single review article (Evidence Level L4), with no clinical trials in DFSP; the model’s own scoring places this candidate at decision stage S1 (“Research Question”). A blocking data gap on TFDA labeling (warnings/contraindications) also prevents a safety pre-assessment.

To proceed, the following is needed:

TFDA package insert data (warnings, contraindications) to resolve the blocking safety data gap
DrugBank-sourced mechanism of action (MOA) detail for nilotinib
Confirmed original indication and DDI profile
Case-series or trial-level clinical evidence of nilotinib specifically in DFSP (beyond the imatinib class-effect analogy)
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.